SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a ...

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for ...

About SYFOVRE® (pegcetacoplan injection) SYFOVRE ® (pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide ...

ONS-5010 (bevacizumab-vikg) was found to be noninferior to ranibizumab for neovascular age-related macular degeneration at week 12.

There are lots of interesting companies that make Bedford their home. Here is a quick recap of what’s happening around town ...

At a single academic tertiary referral center, mild intraocular inflammation developed in four eyes following intravitreal ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

Age-related macular degeneration may cause a gradual reduction in your central vision over time, so you might not recognize AMD at first.

ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK), a clinical-stage biopharmaceutical company with a current market capitalization of $52 million, reported at the Hawaiian Eye and Retina 2025 ...

Dame Judi Dench has given an update on her failing eyesight due to macular disease, admitting that she can no longer leave ...